Asco 2023 – Novartis’s adjuvant breast cancer win comes with caveats
The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.
The sellside hacks back Lynparza’s prostate opportunity
The writing had been on the wall for Parp inhibitors in first-line prostate cancer, and last week’s US panel showed no mercy.
Polivy adcom: no overall survival, no problem
A US adcom surprisingly backs Polivy’s front-line use, and blockbuster sales could follow.